Microplastics and nanoplastics in people with chronic coronary syndromes
Official title: Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes
Run by Azienda Ospedaliera "Sant'Andrea" · NCT07291609 · Data updated 2026-11-12
This study will test whether tiny plastic particles (micro- and nanoplastics) can be detected in the coronary blood of adults with suspected or known chronic coronary syndromes who are having coronary CT and invasive angiography.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Azienda Ospedaliera "Sant'Andrea" Academic / other |
| Locations | 6 sites (Caserta and 5 other locations) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2029 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT07291609 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with suspected or known chronic coronary syndromes who undergo coronary CT angiography and have a clinical indication for invasive coronary angiography and can give informed consent are ideal candidates.
✕Probably not a fit
Patients without a usable coronary CT angiogram, with poor-quality CCTA, without ≥50% native coronary stenosis on CCTA, unable to undergo invasive angiography, or with life expectancy under one year from non-cardiac causes are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational project enrolling adults referred for coronary CT angiography who have a clinical indication for invasive coronary angiography. During invasive angiography, coronary blood samples will be collected and sent to a central core laboratory for centralized analysis of micro- and nanoplastics (MNPs) and related biomarkers. Routine clinical care and treatment decisions will not be changed by participation. Patient dossiers and imaging will be uploaded to a core lab for standardized review and correlation with coronary plaque and stenosis.
Why it matters
Potential benefit: If successful, the findings could reveal whether micro- and nanoplastics are present in coronary blood and suggest a possible environmental contributor to coronary plaque, informing future prevention or diagnostic work.
How similar studies have gone: This is largely a novel approach in coronary disease: a few early human studies have detected microplastics in blood or tissues, but links to coronary plaque and clinical outcomes remain unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: ALL the following: 1. Age \> 18 years old; 2. Suspected or known chronic coronary syndromes undergoing coronary CT angiography; 3. Clinical indication to invasive coronary angiography; 4. Able to give informed consent. Exclusion Criteria: 1. Coronary CT angiography not available; 2. Poor quality CCTA; 3. Absence of native coronary stenosis \>=50% at CCTA; 4. Contraindications to invasive coronary angiography and percutaneous coronary intervention 5. Life expectancy \< 1 year due to non-cardiac pathology
Where it's running
-
Sant'Andrea University Hospital
Roma, Italy Recruiting -
Azienda Ospedaliera Integrata Verona, Italy
Verona, Italy Recruiting -
Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
Caserta, Italy Not yet recruiting -
Cardiovascular Division, Morgagni-Pierantoni University Hospital, Forlì, Italy.
Forlì, Italy Not yet recruiting -
Centro Cardiologico Monzino
Milan, Italy Active not recruiting -
Department of Advanced Medical and Surgical Sciences, University of Campania-Luigi Vanvitelli, Naples, Italy.
Naples, Italy Active not recruiting
Study contacts
- Study coordinator: Emanuele Barbato, MD, PhD
- Email: emanuele.barbato@uniroma1.it
- Phone: +39 0633776115
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating microplastics in patients with heart attacks
This study is testing whether tiny plastic particles found in the body affect heart health in patients who have had a heart attack and are getting urgent treatment.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
Can CZT-SPECT/CT quantify myocardial tracer uptake to match PET measurements in coronary artery disease?
This study tests whether CZT-SPECT/CT can quantify heart blood flow at rest and stress and see if the results align with PET measurements for people with coronary artery disease.
-
AI-driven Medipixel fractional flow reserve to guide PCI
This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.
-
Microplastics in the liver of people with cirrhosis and portal hypertension
This study tests whether microplastics and nanoparticles accumulate in the livers of adults with cirrhosis and portal hypertension who are undergoing surgery or transplant, to understand where they go and what form they take.
-
Identifying biomarkers for high-risk coronary plaques
This study is trying to find new blood markers that can help predict dangerous heart plaque in patients with chronic heart issues or certain types of heart attacks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.